Menstrual-related pain conditions: Dysmenorrhea and migraine

Journal of Women's Health

Volumn 17, Issue 5, 2008, Pages 879-891

  Mannix, Lisa K ^a  

^a Headache Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; CAFFEINE; DANAZOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FROVATRIPTAN; GLYCERYL TRINITRATE; HERBACEOUS AGENT; IBUPROFEN; LEUPRORELIN; MAGNESIUM; MEDROXYPROGESTERONE ACETATE; MEFENAMIC ACID; NAPROXEN; NARATRIPTAN; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE; ROFECOXIB; SUMATRIPTAN; THIAMINE; TRIPTAN DERIVATIVE; UNINDEXED DRUG; VALDECOXIB; VITAMIN B GROUP;

ALGORITHM; CLINICAL FEATURE; CLINICAL TRIAL; DYSMENORRHEA; FEMALE; HUMAN; LOW FAT DIET; MENSTRUAL MIGRAINE; MULTIPLE CYCLE TREATMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW; RISK FACTOR; SYMPTOM; TEA; TRANSCUTANEOUS NERVE STIMULATION; UNITED STATES;

ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DYSMENORRHEA; FEMALE; HUMANS; MENSTRUATION; MIGRAINE DISORDERS; QUALITY OF LIFE; TREATMENT OUTCOME; TRYPTAMINES; UNITED STATES; WOMEN'S HEALTH;

EID: 44949195912     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2007.0440     Document Type: Review

References (115)

1. Kaunitz AM. Menstruation: Choosing whether . . . and when. Contraception 2000;62:277.
2. Dawood MY. Primary dysmenorrhea: Advances in pathogenesis and management. Obstet Gynecol 2006;108:428.
3. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 2001;41:646.
4. Davis AR, Westhoff CL. Primary dysmenorrhea in adolescent girls and treatment with oral contraceptives. J Pediatr Adolesc Gynecol 2001;14:3.
5. French L. Dysmenorrhea. Am Fam Physician 2005;71:285.
6. Slap GB. Menstrual disorders in adolescence. Best Pract Res Clin Obstet Gynaecol 2003;17:75.
7. Durain D. Primary dysmenorrhea: Assessment and management update. J Midwifery Womens Health 2004;49:520.
8. Jabbour HN, Sales KJ, Smith OP, Battersby S, Boddy SC. Prostaglandin receptors are mediators of vascular function in endometrial pathologies. Mol Cell Endocrinol 2006;252:191.
9. Benedetto C. Eicosanoids in primary dysmenorrhea, endometriosis and menstrual migraine. Gynecol Endocrinol 1989;3:71.
10. Harel Z. Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhea. J Pediatr Adolesc Gynecol 2004;17:75.
11. Chan WY, Hill JC. Determination of menstrual prostaglandin levels in nondysmenorrheic and dysmenorrheic subjects. Prostaglandins 1978;15:365.
12. 2alpha and its main metabolites in plasma and endometrium of normal and dysmenorrheic women. Am J Obstet Gynecol 1978;130:640.
13. Rees MC, Anderson AB, Demers LM, Turnbull AC. Prostaglandins in menstrual fluid in menorrhagia and dysmenorrhoea. Br J Obstet Gynaecol 1984;91:673.
14. Granot M, Yarnitsky D, Itskovitz-Eldor J, Granovsky Y, Peer E, Zimmer EZ. Pain perception in women with dysmenorrhea. Obstet Gynecol 2001;98:407.
15. Akerlund M, Stromberg P, Forsling ML. Primary dysmenorrhoea and vasopressin. Br J Obstet Gynaecol 1979;86:484.
16. Rees MC, DiMarzo V, Tippins JR, Morris HR, Turnbull AC. Leukotriene release by endometrium and myometrium throughout the menstrual cycle in dysmenorrhoea and menorrhagia. J Endocrinol 1987;113:291.
17. Ng EY, Tan SL, Kang SH. Laser Doppler imaging of menstrual symptoms. J Med Eng Technol 2003;27:118.
18. Zhang WY, Li Wan Po A. Efficacy of minor analgesics in primary dysmenorrhoea: A systematic review. Br J Obstet Gynaecol 1998;105:780.
19. Ruoff G, Lema M. Strategies in pain management: New and potential indications for COX-2 specific inhibitors. J Pain Symptom Manage 2003;25:S21.
20. Milsom I, Minic M, Dawood MY, et al. Comparison of the efficacy and safety of nonprescription doses of naproxen and naproxen sodium with ibuprofen, acetaminophen, and placebo in the treatment of primary dysmenorrhea: A pooled analysis of five studies. Clin Ther 2002;24:1384.
21. Solomon SD. Cyclooxygenase-2 inhibitors and cardiovascular risk. Curr Opin Cardiol 2006;21:613.
22. Chan WY, Dawood MY. Prostaglandin levels in menstrual fluid of nondysmenorrheic and of dysmenorrheic subjects with and without oral contraceptive or ibuprofen therapy. Adv Prostaglandin Thromboxane Res 1980;8:1443.
23. Chan WY, Dawood MY, Fuchs F. Prostaglandins in primary dysmenorrhea. Comparison of prophylactic and nonprophylactic treatment with ibuprofen and use of oral contraceptives. Am J Med 1981;70:535.
24. Ekstrom P, Akerlund M, Forsling M, Kindahl H, Laudanski T, Mrugacz G. Stimulation of vasopressin release in women with primary dysmenorrhoea and after oral contraceptive treatment - Effect on uterine contractility. Br J Obstet Gynaecol 1992;99:680.
25. Proctor ML, Roberts H, Farquhar CM. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea. Cochrane Database Syst Rev 2001;4:CD002120.
26. Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R, Crosignani PG. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 2003;80:560.
27. Loder E, Rizzoli P, Golub J. Hormonal management of migraine associated with menses and the menopause: A clinical review. Headache 2007;47:329.
28. Coffee AL, Sulak PJ, Kuehl TJ. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 2007;75:444.
29. Sulak PJ, Cressman BE, Waldrop E, Holleman S, Kuehl TJ. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 1997;89:179.
30. Harel Z, Riggs S, Vaz R, Flanagan P, Dunn K, Harel D. Adolescents' experience with the combined estrogen and progestin transdermal contraceptive method Ortho Evra. J Pediatr Adolesc Gynecol 2005;18:85.
31. Transdermal nitroglycerine in the management of pain associated with primary dysmenorrhoea: A multinational pilot study. The Transdermal Nitroglycerine/Dysmenorrhoea Study Group. J Int Med Res 1997;25:41.
32. Moya RA, Moisa CF, Morales F, Wynter H, Ali A, Narancio E. Transdermal glyceryl trinitrate in the management of primary dysmenorrhea. Int J Gynaecol Obstet 2000;69:113.
33. Andersson KE, Ulmsten U. Effects of nifedipine on myometrial activity and lower abdominal pain in women with primary dysmenorrhoea. Br J Obstet Gynaecol 1978;85:142.
34. Proctor ML, Murphy PA. Herbal and dietary therapies for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2001;3:CD002124.
35. Proctor ML, Smith CA, Farquhar CM, Stones RW. Transcutaneous electrical nerve stimulation and acupuncture for primary dysmenorrhoea. Cochrane Database Syst Rev 2002;1:CD002123.
36. Proctor ML, Hing W, Johnson TC, Murphy PA. Spinal manipulation for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2006;3:CD002119.
37. Akin MD, Weingand KW, Hengehold DA, Goodale MB, Hinkle RT, Smith RP. Continuous low-level topical heat in the treatment of dysmenorrhea. Obstet Gynecol 2001;97:343.
38. Akin M, Price W, Rodriguez G Jr, Erasala G, Hurley G, Smith RP. Continuous, low-level, topical heat wrap therapy as compared to acetaminophen for primary dysmenorrhea. J Reprod Med 2004;49:739.
39. Golomb LM, Solidum AA, Warren MP. Primary dysmenorrhea and physical activity. Med Sci Sports Exerc 1998;30:906.
40. Balbi C, Musone R, Menditto A, et al. Influence of menstrual factors and dietary habits on menstrual pain in adolescence age. Eur J Obstet Gynecol Reprod Biol 2000;91:143.
41. Epstein MT, Hockaday JM, Hockaday TD. Migraine and reproductive hormones throughout the menstrual cycle. Lancet 1975;1:543.
42. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992;267:64.
43. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343.
44. Neri I, Granella F, Nappi R, Manzoni GC, Facchinetti F, Genazzani AR. Characteristics of headache at menopause: A clinico-epidemiologic study. Maturitas 1993;17:31.
45. Silberstein SD, Merriam GR. Sex hormones and headache. J Pain Symptom Manage 1993;8:98.
46. MacGregor EA. Oestrogen and attacks of migraine with and without aura. Lancet Neurol 2004;3:354.
47. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology 2006;67:2154.
48. Stewart WF, Lipton RB, Chee E, Sawyer J, Silberstein SD. Menstrual cycle and headache in a population sample of migraineurs. Neurology 2000;55:1517.
49. Dzoljic E, Sipetic S, Vlajinac H, et al. Prevalence of menstrually related migraine and nonmigraine primary headache in female students of Belgrade University. Headache 2002;42:185.
50. Cupini LM, Matteis M, Troisi E, Calabresi P, Bernardi G, Silvestrini M. Sex-hormone-related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura. Cephalalgia 1995;15:140.
51. Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and reproductive life events: A clinical epidemiological study in 1300 women. Headache 1993;33:385.
52. MacGregor EA, Chia H, Vohrah RC, Wilkinson M. Migraine and menstruation: A pilot study. Cephalalgia 1990;10:305.
53. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - Current understanding and treatment. N Engl J Med 2002;346:257.
54. The International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004;24:S139.
55. Edelson RN. Menstrual migraine and other hormonal aspects of migraine. Headache 1985;25:376.
56. Nattero G. Menstrual headache. Adv Neurol 1982;33:215.
57. Waeber C, Moskowitz MA. Migraine as an inflammatory disorder. Neurology 2005;64:S9.
58. Goadsby PJ. The pharmacology of headache. Prog Neurobiol 2000;62:509.
59. Buzzi MG, Moskowitz MA. The pathophysiology of migraine: Year 2005. J Headache Pain 2005;6:105.
60. Silberstein SD. Preventive treatment of headaches. Curr Opin Neurol 2005;18:289.
61. Sarchielli P, Alberti A, Vaianella L, et al. Chemokine levels in the jugular venous blood of migraine without aura patients during attacks. Headache 2004;44:961.
62. Nattero G, Allais G, De Lorenzo C, et al. Menstrual migraine: New biochemical and psychological aspects. Headache 1988;28:103.
63. Sarchielli P, Alberti A, Codini M, Floridi A, Gallai V. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia 2000;20:907.
64. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia 2002;22:54.
65. Peatfield RC, Gawel MJ, Rose FC. The effect of infused prostacyclin in migraine and cluster headache. Headache 1981;21:190.
66. Brandes JL. The influence of estrogen on migraine: A systematic review. JAMA 2006;295:1824.
67. Calhoun AH. Four hypotheses for understanding menstrual migraine. Female Patient 2004;29:38.
68. MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology 2004;63:351.
69. Granella F, Sances G, Allais G, et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia 2004;24:707.
70. Somerville BW. Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration. Neurology 1975;25:239.
71. MacGregor EA. Menstruation, sex hormones, and migraine. Neurol Clin 1997;15:125.
72. Welch KM. Migraine and ovarian steroid hormones. Cephalalgia 1997;17:12.
73. Mannix LK, Files JA. The use of triptans in the management of menstrual migraine. CNS Drugs 2005;19:951.
74. Dowson AJ, Kilminster SG, Salt R, Clark M, Bundy MJ. Disability associated with headaches occurring inside and outside the menstrual period in those with migraine: A general practice study. Headache 2005;45:274.
75. Couturier EG, Bomhof MA, Neven AK, van Duijn NP. Menstrual migraine in a representative Dutch population sample: Prevalence, disability and treatment. Cephalalgia 2003;23:302.
76. Loder E. Prophylaxis of menstrual migraine with triptans: Problems and possibilities. Neurology 2002;59:1677.
77. Mannix LK, Calhoun AH. Menstrual migraine. Curr Treat Options Neurol 2004;6:489.
78. Martin V, Brandes JL. Strategies for optimizing management of menstrual migraine. J Fam Pract 2005;54:S1.
79. Facchinetti F, Sances G, Borella P, Genazzani AR, Nappi G. Magnesium prophylaxis of menstrual migraine: Effects on intracellular magnesium. Headache 1991;31:298.
80. Tepper S. Tailoring management strategies for the patient with menstrual migraine: Focus on prevention and treatment. Headache 2006;46:S61.
81. Lipton RB, Stewart WF, Ryan RE Jr, Saper J, Silberstein S, Sheftell F. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: Three double-blind, randomized, placebo-controlled trials. Arch Neurol 1998;55:210.
82. Allais G, Bussone G, De Lorenzo C, Mana O, Benedetto C. Advanced strategies of short-term prophylaxis in menstrual migraine: State of the art and prospects. Neurol Sci 2005;26:S125.
83. Misra UK, Jose M, Kalita J. Rofecoxib versus ibuprofen for acute treatment of migraine: A randomized placebo controlled trial. Postgrad Med J 2004;80:720.
84. Saper J, Dahlof C, So Y, et al. Rofecoxib in the acute treatment of migraine: A randomized controlled clinical trial. Headache 2006;46:264.
85. Silberstein S, Tepper S, Brandes J, et al. Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology 2004;62:1552.
86. Dodick DW. Acute and prophylactic management of migraine. Clin Cornerstone 2001;4:36.
87. Welch KM. Pathogenesis of migraine. Semin Neurol 1997;17:335.
88. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet 2001;358:1668.
89. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: A race against the development of cutaneous allodynia. Ann Neurol 2004;55:19.
90. Winner P, Mannix LK, Putnam DG, et al. Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies. Mayo Clin Proc 2003;78:1214.
91. Fox AW, Kori SH. Pharmacokinetic opportunities for combination therapy in migraine. Neurology 2005;64:S21.
92. Krymchantowski AV. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr 2000;58:428.
93. Smith TR, Sunshine A, Stark SR, Littlefield DE, Spruill SE, Alexander WJ. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 2005;45:983.
94. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptannaproxen for acute treatment of migraine: a randomized trial. JAMA 2007;297:1443.
95. Smith T, Blumenthal H, Diamond M, et al. Sumatriptan/naproxen sodium for migraine: Efficacy, health-related quality of life, and satisfaction outcomes. Headache 2007;47:683.
96. Winner P, Cady RK, Ruoff GE, et al. Twelve-month tolerability and safety of sumatriptan-naproxen sodium for the treatment of acute migraine. Mayo Clin Proc 2007;82:61.
97. Lay CL, Newman LC. Menstrual migraine: Approaches to management. CNS Drugs 1999;12:189.
98. Sances G, Martignoni E, Fioroni L, Blandini F, Facchinetti F, Nappi G. Naproxen sodium in menstrual migraine prophylaxis: A double-blind placebo controlled study. Headache 1990;30:705.
99. Von Seggern RL, Mannix LK, Adelman JU. Rofecoxib in the prevention of perimenstrual migraine: An open-label pilot trial. Headache 2004;44:160.
100. Newman LC, Lipton RB, Lay CL, Solomon S. A pilot study of oral sumatriptan as intermittent pro-phylaxis of menstruation-related migraine. Neurology 1998;51:307.
101. Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 2004;63:261.
102. Newman L, Mannix LK, Landy S, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: A randomized, double-blind, placebo-controlled study. Headache 2001;41:248.
103. Mannix LK, Savani N, Landy S, et al. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: Data from two randomized, double-blind, placebo-controlled studies. Headache 2007;47:1037.
104. Moschiano F, Allais G, Grazzi L, et al. Naratriptan in the short-term prophylaxis of pure menstrual migraine. Neurol Sci 2005;26:S162.
105. Brandes JL, Smith T, Diamond M, Ames MH. Openlabel, long-term tolerability of naratriptan for shortterm prevention of menstrually related migraine. Headache 2007;47:886.
106. Chavanu KJ, O'Donnell DC. Hormonal interventions for menstrual migraines. Pharmacotherapy 2002;22:1442.
107. de Lignieres B, Vincens M, Mauvais-Jarvis P, Mas JL, Touboul PJ, Bousser MG. Prevention of menstrual migraine by percutaneous oestradiol. Br Med J 1986;293:1540.
108. Dennerstein L, Morse C, Burrows G, Oats J, Brown J, Smith M. Menstrual migraine: A double-blind trial of percutaneous estradiol. Gynecol Endocrinol 1988; 2:113.
109. MacGregor EA, Frith A, Ellis J, Aspinall L. Estrogen " withdrawal": a trigger for migraine? A double-blind placebo-controlled study of estrogen supplements in the late luteal phase in women with migraine [Abstract]. Cephalalgia 2003;23:684.
110. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Prevention of menstrual attacks of migraine: A double-blind placebo-controlled crossover study. Neurology 2006;67:2159.
111. Sulak P, Willis S, Kuehl T, Coffee A, Clark J. Headaches and oral contraceptives: Impact of eliminating the standard 7-day placebo interval. Headache 2007;47:27.
112. Tietjen GE, Conway A, Utley C, Gunning WT, Herial NA. Migraine is associated with menorrhagia and endometriosis. Headache 2006;46:422.
113. Ferrero S, Pretta S, Bertoldi S, et al. Increased frequency of migraine among women with endometriosis. Hum Reprod 2004;19:2927.
114. Tietjen GE, Bushnell CD, Herial NA, Utley C, White L, Hafeez F. Endometriosis is associated with prevalence of comorbid conditions in migraine. Headache 2007;47:1069.
115. Nappi G, Jensen R, Nappi RE, Sances G, Torelli P, Olesen J. Diaries and calendars for migraine. Cephalalgia 2006;26:905.